Targeted therapeutics for severe refractory asthma: monoclonal antibodies-Reference-Cited by-同舟云学术

Targeted therapeutics for severe refractory asthma: monoclonal antibodies

Published:2016-04-14 Issue:7 Volume:9 Page:927-941
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Grainge Christopher L.¹²,Maltby Steven¹,Gibson Peter G.¹²,Wark Peter A. B.¹²,McDonald Vanessa M.¹²

Affiliation:

1. Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs, The University of Newcastle, Newcastle, Australia

2. Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia

Funder

NHMRC Centre of Excellence in Severe Asthma

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1586/17512433.2016.1172208

Reference170 articles.

1. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

2. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry

3. Direct Health Care Costs Associated with Asthma in British Columbia

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced coacervation-driven nanoscale polymeric assemblies for biomedical applications;Applied Physics Reviews;2024-06-01

2. Understanding Breathlessness Burden and Psychophysiological Correlates in Asthma;The Journal of Allergy and Clinical Immunology: In Practice;2024-06

3. Characterization and inhibition of inflammasome responses in severe and non-severe asthma;Respiratory Research;2023-12-04

4. Sexual dimorphism in chronic respiratory diseases;Cell & Bioscience;2023-03-07

5. Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap;Advances in Dermatology and Allergology;2022